SCHEMBL25758526

SCHEMBL25758526

O=S(=O)(NCCCN1CCC(Cc2ccccc2)CC1)c1ccc(-c2ccc(F)cc2)cc1

nearest known ligand 0.58

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CCR3 P51677 6/20 0.58
MEN1 O00255 1/20 0.57
HTT P42858 1/20 0.57
KMT2A Q03164 1/20 0.57
SMN1; SMN2 Q16637 1/20 0.57
SLC6A2 P23975 2/20 0.56
SLC6A4 P31645 2/20 0.56
HTR7 P34969 3/20 0.56
SLC6A3 Q01959 1/20 0.53
HTR1A P08908 2/20 0.53
DRD2 P14416 2/20 0.53
HTR6 P50406 1/20 0.53
DRD4 P21917 1/20 0.50
ADRA1D P25100 1/20 0.50
ADRA1A P35348 1/20 0.50
ADRA1B P35368 1/20 0.50
DRD3 P35462 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24069429 0.94 SLC6A2 (0.63) CCR3MEN1HTTKMT2ASMN1; SMN2
SCHEMBL25290527 0.90 SLC6A2 (0.59) CCR3MEN1HTTKMT2ASMN1; SMN2
SCHEMBL25759276 0.90 PRMT6 (0.56) CCR3MEN1HTTKMT2ASMN1; SMN2
SCHEMBL25758544 0.90 MEN1 (0.69) CCR3MEN1HTTKMT2ASMN1; SMN2
SCHEMBL25758537 0.90 HTR7 (0.58) MEN1HTTKMT2ASMN1; SMN2SLC6A2
SCHEMBL30376178 0.89 HTR7 (0.69) CCR3MEN1HTTKMT2ASMN1; SMN2
SCHEMBL30375512 0.89 TAAR1 (0.53) CCR3SLC6A4HTR7SLC6A3HTR1A
SCHEMBL25759699 0.87 HTR7 (0.59) CCR3MEN1HTTKMT2ASMN1; SMN2
SCHEMBL25758458 0.87 SLC6A2 (0.61) CCR3MEN1HTTKMT2ASMN1; SMN2
SCHEMBL24070124 0.86 MEN1 (0.60) CCR3MEN1HTTKMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230212121-A1 SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING MENTAL ILLNESS TRINEURO (KR) 2023-07-06 US disclosed
US-20230212121-A1 SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING MENTAL ILLNESS TRINEURO (KR) 2023-07-06 US disclosed
EP-4159718-A1 SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING MENTAL ILLNESS Daegu-Gyeongbuk Medical Innovation Foundation (KR) 2023-04-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230212121-A1 SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING MENTAL ILLNESS SLC6A2, SLC6A3, SLC6A4 CCR3 4884/4885MEN1 2054/4885HTT 618/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.